Regenerative InflammationPhase 3NCT03616925
Evaluation of Platelet Rich Fibrin Matrix as Regenerative Material in Intraosseous Defects
A Phase 3 study testing Platelet Rich Fibrin Matrix kit and surgical open flap debridement in people with Regenerative Inflammation, run by KLE Society's Institute of Dental Sciences at 1 site in India.
Trial summary
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Read more about this study
- Who is it for?
- Ages 30 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Regenerative Inflammation
- What is being tested?
- Platelet Rich Fibrin Matrix kit and surgical open flap debridement
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteIndia
- Study dates
- Sep 2013to Nov 2014
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Systemically healthy patients diagnosed with chronic periodontitis.
- Patients with bilateral infra bony pocket measuring ≥ 6mm with radiographic evidence of intrabony defect.
Who cannot join
- Pregnant /lactating women
- Patients taking any drug known to affect the number and function of platelets in the past 3 months.
- Patients with abnormal platelet count.
- Patients with immunologic diseases
- Current smokers.
Trial locations and contacts
1 site in 1 country.
India1 site
Kle Society'S Institute of Dental Sciences
Bengaluru, Karnataka, 560022
About this study
Official title: Evaluation of Platelet Rich Fibrin Matrix(PRFM) as a Regenerative Material in Surgical Management of Human Periodontal Intraosseous Defects:A Randomized Controlled Trial
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood.
Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing.
Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.
Read the detailed description
Periodontitis is a chronic inflammatory disease caused by bacterial Plaque, the onset and progression of which is modulated by a variety of risk factors such as systemic conditions and smoking. It causes pathological alterations of the periodontium, resulting in loss of connective tissue attachment to the tooth, apical migration of the junctional epithelium along the root surface and loss of supporting alveolar bone. If left untreated, cases of periodontal disease can lead to premature tooth loss. However, the complex structure of periodontium, which consist of soft connective tissue of gingiva and periodontal ligament, as well as the mineralized tissues, cementum and bone, makes periodontal wound healing a unique process.
Although, all the tissues of the periodontium get affected, the crux of the problem of chronic periodontal diseases lies in the changes that occur in the bone resulting in intraosseous defects of various architecture, the persistence of which even after completion of active periodontal treatment may increase the site-specific risk of progression of periodontitis.
The two primary components of periodontal therapy involves, the elimination of the periodontal infection by eliminating the pathogenic periodontal microflora which induces favourable clinical changes in the periodontium and substantial efforts should be made to alter the anatomic defect resulting from active periodontitis.
The resective surgical approach and mucogingival surgeries (MGS) were the major periodontal therapies until the 1970s. However, problems with esthetics, root sensitivity and root caries resulting from resective therapy for severe periodontitis were eventually pointed out. Also resective procedure was admitted to be a "Repair" and not "Regeneration" which has long been the goal of periodontal therapy. The past two decades has seen a radical change in periodontal surgery with a shift from resective periodontal surgery to regenerative therapies. Also the concept of treatment has changed towards regeneration with a goal of regaining natural periodontal apparatus.
Conventional surgical approaches (e.g., flap debridement) continue to offer time-tested and reliable methods to access root surfaces, reduce periodontal pockets and attain improved periodontal form/architecture. However, these techniques offer only limited potential to recover tissues, destroyed during earlier disease phases.
Broad ranges of treatment options are available, but only some are regarded as truly regenerative procedures. Periodontal regeneration is a complex process which requires an orchestrated sequence of biologic events, such as cell migration, adherence, growth, and differentiation involving a large number of growth factors and cytokines for its regulation.To accelerate clinical translation of the same, there is an ongoing need to develop therapeutics based on endogenous regenerative technology (ERT), which can stimulate latent self-repair mechanisms in patients and harness the host's innate capacity for regeneration. ERT in periodontics applies the patient's own regenerative 'tools', that is, patient-derived growth factors (GFs) and fibrin scaffolds, to create a material niche in an injured site where the progenitor/stem cells from neighbouring tissues can be recruited for (in situ) periodontal regeneration.
Growth factors are naturally occurring proteins that function in the body to promote the mitogenesis (proliferation), directed migration and metabolic activity of cells. Numerous growth factors have been identified, the expression of which following bone and soft tissue injury may regulate the repair and regenerative process. Platelets apart from their role in haemostasis have been reported to possess regenerative potential as their alpha granules are rich sources of various vital growth factors. These growth factors such as platelet derived growth factor, transforming growth factor β1, epithelial growth factor, vascular endothelial growth factor, insulin like growth factor and fibroblast growth factor whether used alone or in combination have been extensively studied and shown to promote the regeneration of oral and maxillofacial bone defects. Platelet growth factors may initiate healing by attracting undifferentiated cells within the fibrin matrix that is formed in the very early stages of healing process and by triggering cell division.
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood.
Currently several methods are available for PRP preparation, most producing a liquid end product to promote tissue repair. Due to poor mechanical properties, conventional PRP is often difficult to handle in clinical settings that require secure implantation in a specific site or where released growth factors could be washed out during an operation. The physical properties of PRP can be changed if plasma and platelets are stimulated by the addition of calcium chloride and thrombin. The exogenous activation of platelets using bovine thrombin at the time of PRP preparation result in an almost immediate degranulation and disintegration of platelet granules. Consequently, complete growth factor release will take place at the time of PRP preparation and placement. Since wound healing requires a sequential appearance of vessels and cells over time, the immediate and almost complete release of platelet granules may have very little beneficial effect on later stages of healing.
In contrast, Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing.
Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.
- Conditions
- Regenerative Inflammation
- Being tested
- Platelet Rich Fibrin Matrix kit, surgical open flap debridement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Platelet Rich Fibrin Matrix kitBiological
Also called centrifugation machine
Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
surgical open flap debridementProcedure or surgery
only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
| Study group | Role | What they receive |
|---|---|---|
| Platelet rich fibrin matrix | Experimental | surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites Receives: Biological: Platelet Rich Fibrin Matrix kit |
| surgical open flap debridement | Active comparator | only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites Receives: Procedure: surgical open flap debridement |
What is being measured
The primary outcome is the main question the study is designed to answer.
the clinical change in regenerative potential of platelet rich fibrin matrix (PRFM) and open flap debridement (OFD) and OFD alone in periodontal defects.
Clinical parameters(plaque index, gingival index, probing pocket depth,attachment level)were combined to assess the change in the regenerative potential
Measured: baseline,3 months and 6 months
Early wound healing index (EHI) was used to assess the wound healing potential of PRFM
Early wound healing index (EHI) was used to assess the wound healing potential of PRFM at 1 week.
Measured: 1 week
change in the radiographic parameters in both the groups i.e,PRFM+OFD and OFD alone
radiographic evidence of bilateral vertical osseous defects were categorized into test group [OFD + PRFM and control group [open flap debridement (OFD)]
Measured: baseline,3 months,6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2018
- Study startSep 2013
- Primary completionSep 2014
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Regenerative InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The patients for this study were selected from the outpatient section of the Department of Periodontics, KLE Society's institute of Dental Sciences, Bangalore, Karnataka. Fifteen patients, aged between 30-55 years (10 males and 5 females) diagnosed with chronic periodontitis, contributing to 30 sites were enrolled for the study by convenience sampling method. It was made clear to the potential subjects that participation was voluntary. Written informed consent was obtained from patients, and ethical clearance for the study was received from the Institutional Ethics Committee (IEC), KLE Society's institute of Dental Sciences, Bangalore. This Randomized controlled trial was carried out from November 2013 to October 2014.
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- KLE Society's Institute of Dental Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Laveena Singhal, KLE Society's Institute of Dental Sciences
- Investigators
- Komal D Walia, MDS, Principal investigator, KLE Society's Institute of Dental Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03616925
- Sponsor's protocol ID
- KLESociety
- Status last verified
- Aug 2018
- First submitted
- 8 Apr 2018
- Last updated
- 6 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: except the results
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Platelet Rich Fibrin Matrix(PRFM) as a Regenerative Material in Surgical Management of Human Periodontal Intraosseous Defects:A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03616925
- Acronym / sponsor ID
- KLESociety
- Conditions
- Regenerative Inflammation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- KLE Society's Institute of Dental SciencesUniversity, hospital or other
- Study start
- Sep 2013 (actual)
- Primary completion
- Sep 2014 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 6 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood.
Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing.
Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.
Detailed description
Periodontitis is a chronic inflammatory disease caused by bacterial Plaque, the onset and progression of which is modulated by a variety of risk factors such as systemic conditions and smoking. It causes pathological alterations of the periodontium, resulting in loss of connective tissue attachment to the tooth, apical migration of the junctional epithelium along the root surface and loss of supporting alveolar bone. If left untreated, cases of periodontal disease can lead to premature tooth loss. However, the complex structure of periodontium, which consist of soft connective tissue of gingiva and periodontal ligament, as well as the mineralized tissues, cementum and bone, makes periodontal wound healing a unique process.
Although, all the tissues of the periodontium get affected, the crux of the problem of chronic periodontal diseases lies in the changes that occur in the bone resulting in intraosseous defects of various architecture, the persistence of which even after completion of active periodontal treatment may increase the site-specific risk of progression of periodontitis.
The two primary components of periodontal therapy involves, the elimination of the periodontal infection by eliminating the pathogenic periodontal microflora which induces favourable clinical changes in the periodontium and substantial efforts should be made to alter the anatomic defect resulting from active periodontitis.
The resective surgical approach and mucogingival surgeries (MGS) were the major periodontal therapies until the 1970s. However, problems with esthetics, root sensitivity and root caries resulting from resective therapy for severe periodontitis were eventually pointed out. Also resective procedure was admitted to be a "Repair" and not "Regeneration" which has long been the goal of periodontal therapy. The past two decades has seen a radical change in periodontal surgery with a shift from resective periodontal surgery to regenerative therapies. Also the concept of treatment has changed towards regeneration with a goal of regaining natural periodontal apparatus.
Conventional surgical approaches (e.g., flap debridement) continue to offer time-tested and reliable methods to access root surfaces, reduce periodontal pockets and attain improved periodontal form/architecture. However, these techniques offer only limited potential to recover tissues, destroyed during earlier disease phases.
Broad ranges of treatment options are available, but only some are regarded as truly regenerative procedures. Periodontal regeneration is a complex process which requires an orchestrated sequence of biologic events, such as cell migration, adherence, growth, and differentiation involving a large number of growth factors and cytokines for its regulation.To accelerate clinical translation of the same, there is an ongoing need to develop therapeutics based on endogenous regenerative technology (ERT), which can stimulate latent self-repair mechanisms in patients and harness the host's innate capacity for regeneration. ERT in periodontics applies the patient's own regenerative 'tools', that is, patient-derived growth factors (GFs) and fibrin scaffolds, to create a material niche in an injured site where the progenitor/stem cells from neighbouring tissues can be recruited for (in situ) periodontal regeneration.
Growth factors are naturally occurring proteins that function in the body to promote the mitogenesis (proliferation), directed migration and metabolic activity of cells. Numerous growth factors have been identified, the expression of which following bone and soft tissue injury may regulate the repair and regenerative process. Platelets apart from their role in haemostasis have been reported to possess regenerative potential as their alpha granules are rich sources of various vital growth factors. These growth factors such as platelet derived growth factor, transforming growth factor β1, epithelial growth factor, vascular endothelial growth factor, insulin like growth factor and fibroblast growth factor whether used alone or in combination have been extensively studied and shown to promote the regeneration of oral and maxillofacial bone defects. Platelet growth factors may initiate healing by attracting undifferentiated cells within the fibrin matrix that is formed in the very early stages of healing process and by triggering cell division.
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood.
Currently several methods are available for PRP preparation, most producing a liquid end product to promote tissue repair. Due to poor mechanical properties, conventional PRP is often difficult to handle in clinical settings that require secure implantation in a specific site or where released growth factors could be washed out during an operation. The physical properties of PRP can be changed if plasma and platelets are stimulated by the addition of calcium chloride and thrombin. The exogenous activation of platelets using bovine thrombin at the time of PRP preparation result in an almost immediate degranulation and disintegration of platelet granules. Consequently, complete growth factor release will take place at the time of PRP preparation and placement. Since wound healing requires a sequential appearance of vessels and cells over time, the immediate and almost complete release of platelet granules may have very little beneficial effect on later stages of healing.
In contrast, Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing.
Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The patients for this study were selected from the outpatient section of the Department of Periodontics, KLE Society's institute of Dental Sciences, Bangalore, Karnataka. Fifteen patients, aged between 30-55 years (10 males and 5 females) diagnosed with chronic periodontitis, contributing to 30 sites were enrolled for the study by convenience sampling method. It was made clear to the potential subjects that participation was voluntary. Written informed consent was obtained from patients, and ethical clearance for the study was received from the Institutional Ethics Committee (IEC), KLE Society's institute of Dental Sciences, Bangalore. This Randomized controlled trial was carried out from November 2013 to October 2014.
| Arm | Type | Receives |
|---|---|---|
| Platelet rich fibrin matrix | Experimental | Biological: Platelet Rich Fibrin Matrix kitsurgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites |
| surgical open flap debridement | Active comparator | Procedure: surgical open flap debridementonly surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Systemically healthy patients diagnosed with chronic periodontitis.
- Patients with bilateral infra bony pocket measuring ≥ 6mm with radiographic evidence of intrabony defect.
Key exclusion criteria (5 listed)
- Pregnant /lactating women
- Patients taking any drug known to affect the number and function of platelets in the past 3 months.
- Patients with abnormal platelet count.
- Patients with immunologic diseases
- Current smokers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Platelet Rich Fibrin Matrix kitAlso: centrifugation machinePlatelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine | Biological | Platelet rich fibrin matrix |
| surgical open flap debridementonly surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit | Procedure or surgery | surgical open flap debridement |
Primary outcome
the clinical change in regenerative potential of platelet rich fibrin matrix (PRFM) and open flap debridement (OFD) and OFD alone in periodontal defects.
Time frame: baseline,3 months and 6 months
Clinical parameters(plaque index, gingival index, probing pocket depth,attachment level)were combined to assess the change in the regenerative potential
Early wound healing index (EHI) was used to assess the wound healing potential of PRFM
Time frame: 1 week
Early wound healing index (EHI) was used to assess the wound healing potential of PRFM at 1 week.
change in the radiographic parameters in both the groups i.e,PRFM+OFD and OFD alone
Time frame: baseline,3 months,6 months
radiographic evidence of bilateral vertical osseous defects were categorized into test group [OFD + PRFM and control group [open flap debridement (OFD)]
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2018.
- Individual participant dataSharing planned: Undecided. except the results
Related trials for Regenerative Inflammation
RecruitingObservational study
Systemic Biochemical Signature and Functional Quality Index of Calcaneal Bone Marrow Aspirate in Adults Undergoing Foot or Ankle Surgery
Diabetic Foot Ulcer, Wound Healing
Not yet recruitingPhase 3
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).
Acute Respiratory Distress Syndrome
Not yet recruitingObservational study
Measurement of Pro-resolving Inflammation Biomarkers in Saliva, Gingival Fluid, and Dental Pulp in Patients With Symptomatic Pulpitis and Healthy Controls
Pulpitis, Healthy
Active, not recruitingObservational study
Longitudinal Evaluation of Regenerative Treatment of Peri-implantitis Assited by Er,Cr:YSGG Laser: up to 10 Years Follow-up
Peri-Implantitis and Peri-implant Mucositis, Peri-Implantitis and Systemic Inflammation
RecruitingPhase 2
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Komal D Walia, MDS principal investigator
KLE Society's Institute of Dental Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Platelet Rich Fibrin Matrix kit and surgical open flap debridement in people with Regenerative Inflammation, run by KLE Society's Institute of Dental Sciences at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the clinical change in regenerative potential of platelet rich fibrin matrix (PRFM) and open flap debridement (OFD) and OFD alone in periodontal defects. (time frame: baseline,3 months and 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2018.